Normal human immunoglobulins for intravenous use (IVIg) delay hyperacute xenograft rejection through F(ab')2-mediated anti-complement activity

Clin Exp Immunol. 1997 Oct;110(1):122-6. doi: 10.1046/j.1365-2249.1997.4591358.x.

Abstract

Xenotransplantation between discordant species leads to a hyperacute rejection mediated by natural antibodies, both of the IgG and IgM isotypes, activation of complement and endothelial cell activation. The combination of these mechanisms leads to a transplant survival of minutes to a few hours. Polyclonal human immunoglobulins for intravenous use (IVIg) from normal donors have proved effective in a number of antibody-mediated disorders, as well as in inflammatory disorders. We demonstrate that administration of IVIg in a guinea pig to rat model of cardiac xenografting can effectively delay hyperacute rejection. This effect is mediated by the F(ab')2 fragments of IVIg, and is correlated to an anti-complementary activity.

MeSH terms

  • Acute Disease
  • Animals
  • Complement Activation*
  • Female
  • Graft Rejection / immunology*
  • Graft Rejection / prevention & control*
  • Guinea Pigs
  • Heart Transplantation*
  • Humans
  • Immunoglobulin Fab Fragments / immunology*
  • Immunoglobulins, Intravenous / administration & dosage*
  • Male
  • Rats
  • Rats, Inbred Lew
  • Transplantation, Heterologous

Substances

  • Immunoglobulin Fab Fragments
  • Immunoglobulins, Intravenous